Analysts See Multiple Growth Levers For CVS In 2026 - CVS Health (NYSE:CVS)

Analysts See Multiple Growth Levers For CVS In 2026 - CVS Health (NYSE:CVS)

CVS Health Corp. (NYSE:CVS) reported sales of $105.69 billion, beating the consensus of $103.59 billion on Tuesday. Adjusted earnings of $1.09 per share also beat the analyst estimate of 99 cents, decreased from $1.19 in the prior year. CVS Health reaffirmed its fiscal 2026 adjusted earnings guidance of $7.00-$7.20 per share versus the Street consensus of $7.17. The company said the guidance highlights our strong position for 2026. The company u…

The CVS Earnings Bombshell That Has Investors Scrambling Right Now

Quick Read CVS Health (CVS) beat Q4 revenue expectations at $105.69B. Adjusted earnings fell to $1.09 from $1.19 prior year. CVS’s Health Care Benefits segment posted a $676M operating loss and shed 504,000 members year-over-year. CVS reduced 2026 operating cash flow guidance to at least $9.0B from a prior $10.0B target. At a Glance Revenue: $105.69 billion (beat consensus of $104.63 billion) Adjusted EPS: $1.09 (beat consensus of $1.00) GAA…

CVS Health beats quarterly profit expectations on pharmacy performance

Feb 10 (Reuters) – CVS Health reported a decline in fourth-quarter profit on Tuesday but beat Wall Street estimates, helped by strength in its pharmacy benefit unit and strong prescription volume at its retail pharmacies. CVS said adjusted ‍quarterly profit fell to $1.09 per share from $1.19, above analysts’ average estimate of 99 cents per share, according to data compiled by LSEG. “I talk about a Say-Do ratio,” said Chief Financial Officer Bri…

CVS tops quarterly estimates, reaffirms profit outlook as turnaround plan takes effect

The results signal steady progress in the health-care giant's aggressive turnaround plan under CEO David Joyner, who stepped into the role in late 2024.

CVS Health continues to improve health following strong Q4

Purchase of Rite Aid and Bartell Drugs assets has boosted performance